

## Total Synthesis of (+)-Cylindramide A

Amy C. Hart and Andrew J. Phillips\*

Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 80309-0215

Received December 1, 2005; E-mail: Andrew.Phillips@colorado.edu

In 1993, Fusetani and co-workers described the structure of cylindramide A, a macrocyclic tetramic acid isolated from the sponge *Halichondria cylindrata* that was cytotoxic to B16 melanoma cells with an  $IC_{50}$  of  $0.8 \mu\text{g mL}^{-1}$ .<sup>1a</sup> Cylindramide A is structurally related to a number of other tetramic acid-containing macrolactams that have been isolated from a variety of sources, including aburatubolactam A,<sup>1b</sup> geodin A,<sup>1c</sup> xanthobaccin A,<sup>1d</sup> ikarugamycin,<sup>1e</sup> discoderamide,<sup>1f</sup> and the alteramides.<sup>1g</sup> Because of their complex structures and diverse biological activities including cytotoxicity, antimicrobial activity, and inhibition of superoxide generation, these compounds have generated a significant degree of interest in the synthesis community,<sup>2</sup> and in this Communication we report a synthesis of cylindramide A.

Our strategy for the synthesis of cylindramide A is outlined in Figure 1. We planned to couple two large domains: a subunit containing the bicyclo[3.3.0]octene (**4**), and a 3-hydroxyornithine-derived subunit (**5**). The bicyclo[3.3.0]octene ring system was envisioned to arise from a tandem ring-opening–ring-closing–cross metathesis (ROM–RCM–CM) of readily available norbornene **2** to give **3**.<sup>3</sup>





Figure 1. Structure of cylindramide A (**1**) and synthetic strategy.

Norbornene **2** was obtained by a five-step sequence that was initiated by the cross metathesis of acryloyl oxazolidinone **6** with alkene **7** to give **8** in 59% yield (Scheme 1). Diels–Alder reaction with cyclopentadiene under the conditions described by Evans led to **9** (96%, dr = 45:1).<sup>4</sup> Although direct conversion of the oxazolidinone to Weinreb amide **10** was not possible, simple hydrolysis to the acid and a 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDCI)-mediated coupling provided a suitable alternative (52% over two steps). Addition of vinylmagnesium bromide to a solution of **10** at reflux provided **2** in 98% yield and set the stage for the key tandem ROM–RCM–CM sequence.


When **2** was treated with 4 mol % Grubbs's catalyst in the presence of 3.0 equiv of **11**, tandem ROM–RCM–CM occurred to give **3** in 59% yield and as a 2:1 mixture of separable diastereoisomers (Scheme 2).

### Scheme 1<sup>a</sup>



<sup>a</sup> Reagents and conditions: (1) 10% Grubbs's II catalyst, **7**,  $\text{CH}_2\text{Cl}_2$ ,  $40^\circ\text{C}$ , 59%; (2) cyclopentadiene,  $\text{Et}_2\text{AlCl}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $-78^\circ\text{C}$ , 96%, dr = 45:1; (3) (a)  $\text{LiOH}$ ,  $\text{H}_2\text{O}_2$ , THF,  $\text{H}_2\text{O}$ ,  $-10^\circ\text{C}$ ; (b)  $\text{HCl}\cdot\text{HN}(\text{OMe})\text{Me}$ , DMAP, EDCI,  $\text{CH}_2\text{Cl}_2$ , 52% (two steps); (4)  $\text{H}_2\text{C}=\text{CHMgBr}$ , THF,  $67^\circ\text{C}$ , 98%.


### Scheme 2<sup>a</sup>



<sup>a</sup> Reagents and conditions: 4% Grubbs's catalyst, **11** (3.0 equiv),  $\text{CH}_2\text{Cl}_2$ ,  $40^\circ\text{C}$ , 59%.

Conversion of **3** to **4** commenced with installation of the C17 methyl group and  $\Delta^{15,16}$  olefin by a sequence consisting of conjugate addition ( $\text{Me}_2\text{CuLi}$ , 90%, Scheme 3) followed by ketone reduction and elimination of the resultant secondary alcohol ( $\text{NaBH}_4$  and then Martin sulfurane,<sup>5</sup> 53%) to give **16**. Removal of the triisopropylsilyl (TIPS) ether with  $\text{HF}$ /pyridine provided alcohol **17** in 86% yield. Oxidation with tetrapropylammonium perruthenate/*N*-methylmorpholine *N*-oxide (TPAP/NMO), followed by immediate reaction with [bis(2,2,2-trifluoroethoxy)phosphoryl]acetic acid (2-trimethylsilyl)ethyl ester<sup>6</sup> under Still–Gennari conditions,<sup>7</sup> yielded **18** in 51% yield for the two steps. Cleavage of the 2-(trimethylsilyl)ethyl (TMSE) group with tetrabutylammonium fluoride (TBAF) and reduction of the isobutyl chloroformate-derived mixed anhydride with  $\text{NaBH}_4$  (**18**→**19**, 51% over two steps), followed by Dess–Martin oxidation, gave **4** and completed the synthesis of the bicyclo[3.3.0]octene domain.

Coupling of key fragments **4** and **5**<sup>8</sup> was achieved by Horner–Wadsworth–Emmons reaction, which led to **20** in 90% overall yield from allylic alcohol **19**. Heating **20** in toluene at reflux under dilute conditions resulted in macrocyclization to give the expected  $\beta$ -ketoamide in 65% yield as a complex mixture of tautomers. Removal of the *tert*-butyldimethylsilyl (TBS) ether with  $\text{HF}$  provided **21** in 95% yield. The synthesis was completed by Lacey–Dieckmann cyclization<sup>9</sup> to form the tetramic acid ( $\text{NaOMe}$ , 90%), and finally removal of the 2,4-dimethoxybenzyl protecting group (trifluoroacetic acid (TFA),  $67^\circ\text{C}$ , 65%) provided cylindramide

Scheme 3<sup>a</sup>

<sup>a</sup> Reagents and conditions: (1) (a)  $\text{Me}_2\text{CuLi}$ ,  $\text{Et}_2\text{O}$ ,  $-78^\circ\text{C}$ , 90%; (b)  $\text{NaBH}_4$ ,  $\text{MeOH}$ ,  $0^\circ\text{C}$ ; (c) Martin sulfuran,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ , 53% (two steps); (2)  $\text{HF}/\text{pyr}$ ,  $\text{THF}$ , 86%; (3) (a) TPAP, NMO,  $\text{CH}_2\text{Cl}_2$ , 4 Å MS; (b) [bis(2,2,2-trifluoroethoxy)phosphoryl]acetic acid (2-trimethylsilyl)ethyl ester, KHMDS, 18-C-6,  $\text{THF}$ ,  $-78^\circ\text{C}$ , 51% (two steps); (4) (a) TBAF,  $\text{THF}$ ; (b) IBCF, NMM,  $\text{THF}$ ,  $0^\circ\text{C}$ , then  $\text{NaBH}_4$ ,  $\text{MeOH}$ ,  $\text{H}_2\text{O}$ , 50% (two steps); (5) Dess–Martin periodinane,  $\text{CH}_2\text{Cl}_2$ ; (6) **5**, NaHMDS, then add **4**,  $\text{THF}$ ,  $-78^\circ\text{C} \rightarrow \text{rt}$ , 90% (from **19**); (7) (a)  $\text{PhMe}$ ,  $105^\circ\text{C}$ , 65%; (b)  $\text{HF}$ ,  $\text{MeCN}$ , 95%; (8) (a)  $\text{NaOMe}$ ,  $\text{MeOH}$ , 90%; (b)  $\text{TFA}$ ,  $67^\circ\text{C}$ , 65%.

A. Synthetic cylindramide A had physical and spectroscopic properties in accord with those reported.<sup>10</sup>

In conclusion, we have delineated a synthesis of cylindramide A that proceeds in 19 steps (longest linear sequence) and highlights the utility of the tandem ROM–RCM–CM of simple norbornenes in the context of complex natural products synthesis.

**Acknowledgment.** We thank Dr. Gillian Nicholas for experimental assistance and Professor Nobuhiro Fuestani for copies of spectra for cylindramide A. This research was supported by the National Cancer Institute (NCI CA110246) and in part by The American Chemical Society Petroleum Research Fund (ACS PRF# 38856-G1) and was facilitated by NMR facilities purchased partly with a NSF Shared Instrumentation Grant (CHE-0131003).

**Supporting Information Available:** Experimental procedures, data, and spectra for compounds **1–3**, **8–10**, and **16–21**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- (1) (a) Kanazawa, S.; Fusetani, N.; Matsunaga, S. *Tetrahedron Lett.* **1993**, *34*, 1065. (b) Bae, M. A.; Yamada, K.; Ijuin, Y.; Tsuji, T.; Yazawa, K.; Tomono, Y.; Uemura, D. *Heterocycl. Commun.* **1996**, *2*, 315. (c) Capon, R. J.; Skene, C.; Lacey, E.; Gill, J. H.; Wadsworth, D.; Friedel, T. *J. Nat. Prod.* **1999**, *62*, 1256. (d) Hashidoko, Y.; Nakayama, T.; Homma, Y.; Tahara, S. *Tetrahedron Lett.* **1999**, *40*, 2957. (e) Jomon, K.; Kuroda, Y.; Ajisaka, M.; Sakai, H. *J. Antibiot.* **1972**, *25*, 271. (f) Gunasekera, S. P.; Gunasekera, M.; McCarthy, P. *J. Org. Chem.* **1991**, *56*, 4830. (g) Shigemori, H.; Bae, M. A.; Yazawa, K.; Sasaki, T.; Kobayashi, J. *J. Org. Chem.* **1992**, *57*, 4317.
- (2) For a previous synthesis of cylindramide A, see: (a) Cramer, N.; Laschat, S.; Baro, A.; Schwalbe, H.; Richter, C. *Angew. Chem., Int. Ed.* **2005**, *44*, 820. For syntheses of ikarugamycin, see: (b) Boeckman, R. K., Jr.; Weidner, C. H.; Perni, R. B.; Napier, J. J. *J. Am. Chem. Soc.* **1989**, *111*, 8036. (c) Paquette, L. A.; Macdonald, D.; Anderson, L. G.; Wright, J. J. *Am. Chem. Soc.* **1989**, *111*, 8037. (d) Roush, W. R.; Wada, C. K. *J. Am. Chem. Soc.* **1994**, *116*, 2151.
- (3) For other examples of tandem metathesis sequences of this general type, see: (a) Stragies, R.; Blechert, S. *Synlett.* **1998**, 169. (b) Wroblecki, A.; Sahasrabudhe, K.; Aubé, J. *J. Am. Chem. Soc.* **2002**, *124*, 9974. (c) Arjona, O.; Csaky, A. G.; Medel, R.; Plumet, J. *J. Org. Chem.* **2002**, *67*, 1380. (d) Stille, J. R.; Santarsiero, B. D.; Grubbs, R. H. *J. Org. Chem.* **1990**, *55*, 843. (e) Minger, T. L.; Phillips, A. J. *Tetrahedron Lett.* **2002**, *43*, 5357 and references therein.
- (4) Evans, D. A.; Chapman, K. T.; Bisaha, J. *J. Am. Chem. Soc.* **1984**, *106*, 4261.
- (5) Martin, J. C.; Arhart, R. J. *J. Am. Chem. Soc.* **1971**, *93*, 4327.
- (6) Boger, D. L.; Sakya, S. M.; Yohannes, D. *J. Org. Chem.* **1991**, *56*, 4204.
- (7) Still, W. C.; Gennari, C. *Tetrahedron Lett.* **1983**, *24*, 4405.
- (8) Amine **5** was synthesized by the sequence shown below:
 

R = Boc  
5, R = COCH<sub>2</sub>PO(OEt)<sub>2</sub>
- (9) Lacey, R. N. *J. Chem. Soc.* **1954**, 850.
- (10) See the Supporting Information for details.

JA057899A